SCM
BMRN icon

Shelton Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shelton Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,800
Closed -$231K – 758
2016
Q1 		$231K Hold
2,800
– – 0.02% 658
2015
Q4 		$293K Buy
+2,800
New +$292K 0.03% 549

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shelton Capital Management's BMRN Position: Q1 2026 in Review

Shelton Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 6,406 shares worth $362K. The position accounts for 0.01% of the portfolio, ranked #453.

Shelton Capital Management first reported a position in BMRN in Q2 2013 and has held it in 36 quarters since. The position peaked at $10.8M in Q3 2013. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Shelton Capital Management held 6,406 shares of BioMarin Pharmaceuticals worth $362K as of Q1 2026.
  • Shelton Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Shelton Capital Management's portfolio in Q1 2026, its #453 holding.
  • Shelton Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Shelton Capital Management's BioMarin Pharmaceuticals position peaked at $10.8M in Q3 2013.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Shelton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.